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This bulletin presents key findings regarding polydrug use (the use of more than one substance within a specific 
time period) in Ireland. These are based on the drug prevalence survey of households in Ireland and Northern 
Ireland. A representative sample of adults aged between 15 and 64 years was sampled during late 2010 and early 
2011. The bulletin presents prevalence rates for combinations of both legal and illegal drug use for the Republic 
of Ireland and also examines gender and age differences and the relationship between the use of a particular 
substance and the use of another substance. The survey was carried out according to standards set by the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Key findings
It should be noted that the key findings 
are presented according to the order of 
the bulletin contents and are not intended 
to be indicative of the relative importance 
of the findings. It should also be noted 
that the figures presented for prevalence 
are for that specific combination only and 
do not provide information on individual 
substances unless specified.
n Twenty percent of all adults aged 15-64 
in Ireland had not used any substance 
(legal or illegal) within the last month.
n Alcohol and tobacco use was the most 
common combination of substance use 
reported among all adults (16%).
n Four percent of all adults had used 
tobacco only within the last month.
n Among all adults, the last month 
prevalence of polydrug use which 
included any illegal drug was 3%.
n Females (23%) were more likely than 
males (16%) not to have used any 
substance (legal or illegal) during the 
last month.
n Last month prevalence of alcohol 
and tobacco use was higher among 
men (20%) than women (13%) and 
among young adults than older adults 
(18% vs. 15% respectively).
n Last month prevalence of alcohol, 
tobacco, and any illegal drug was 
higher among men (3%) than women 
(0.4%) and among young adults (3%) 
than older adults (1%).
n Older adults were more likely than 
younger adults to use the combination 
of alcohol and anti-depressants.
n There were statistically significant 
differences in prevalence rates of 
polydrug use among men and women 
and among young and older adults.
n Of those who had smoked tobacco, 
78% had also used alcohol in the last 
month.
n Of those who had used cannabis 85% 
had also used alcohol and 77% had 
also smoked tobacco in the last month.
n Since 2006/7 there have been 
statistically significant decreases in the 
use of tobacco among users of alcohol, 
the use of tobacco among users of 
cannabis and the use of alcohol among 
users of tobacco. Findings were similar 
for men and young adults.
n Users of cannabis, users of 
amphetamine-type stimulants and 
users of cocaine were likely to have 
used other legal as well as illegal 
substances in the last month.
n Users of sedatives or tranquillisers and 
users of anti-depressants were likely to 
have used other legal substances.
n Among users of alcohol males were 
more likely than females to have also 
used cannabis.
n Among users of alcohol females were 
more likely than males to have also 
used anti-depressants.
n There were statistically significant 
differences in the use of another 
substance among young and older 
adult users of alcohol.
n Among young and older adults who 
smoked tobacco there were statistically 
significant differences in their use of 
another substance as well.
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Introduction
The survey was commissioned by the National Advisory 
Committee on Drugs (NACD) in Ireland and the Public Health 
Information & Research Branch (PHIRB) within the Department 
of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland. This bulletin presents results for the Republic of 
Ireland only.
In 2013 NACD was reconstituted until the end of 2016, in line 
with the time frame of the National Drugs Strategy. The remit 
of the Committee was extended to include alcohol and is now 
called the National Advisory Committee on Drugs and Alcohol 
(NACDA).
The role of the new committee is to advise Government 
on the prevalence, prevention, treatment, rehabilitation and 
consequences of substance use and misuse in Ireland, based on 
the analysis of research findings and other information available 
to it.
The main purpose of the survey was to obtain prevalence rates 
for key illegal drugs, on a lifetime (ever used), last year (recent 
use), and last month (current use) basis. The survey also 
covered prescription drugs including sedatives or tranquillisers 
and anti-depressants. Similar prevalence questions were asked 
for alcohol, tobacco, and other drugs.
About the Drug Prevalence Survey
The questionnaire and methodology for the general population 
survey were based on best practice guidelines drawn up by the 
EMCDDA. The questionnaires were administered through face-
to-face interviews with respondents aged between 15 and 64 
years and who are normally resident in households in Ireland 
and Northern Ireland. Thus persons outside these age ranges, or 
who do not normally live in private households, have not been 
included in the survey (for example prisons, nursing homes etc).
Fieldwork for the survey was carried out between October 2010 
and May 2011 and the final sample achieved comprised of 
7,669 respondents (5,134 in Ireland and 2,535 in Northern 
Ireland). Interviews were conducted using computer-assisted 
personal interviewing (CAPI). These techniques allow interviews 
to be conducted more efficiently and more accurately than other 
techniques such as pen-and-paper completion.
The response rate for the survey was 60% in Ireland and 67% 
in Northern Ireland. Area based sampling was applied in Ireland. 
The first stage involved stratifying by Health Board in Ireland1. 
The achieved sample was weighted by gender, age and region2 
in Ireland and by gender, age and Health and Social Care Trust 
area in Northern Ireland3 to maximise representativeness of the 
general population.
Details of the methodology have been summarised in a paper 
published on the websites of the NACDA (http://www.nacda.ie/) 
and the DHSSPS (http://www.dhsspsni.gov.uk/).
What is Prevalence?
The term prevalence refers to the proportion of  
a population who have used a drug over a particular  
time period. In general population surveys prevalence  
is measured by asking respondents in a representative 
sample drawn from the population to recall their use of 
drugs. The three most widely used recall periods are: 
lifetime (ever used a drug), last year (used a drug in the  
last twelve months), and last month (used a drug in the last 
30 days). Provided that a sample is representative of the 
total population, prevalence information obtained from a 
sample can be used to infer prevalence in the population.
Lifetime prevalence refers to the proportion of the  
sample that reported ever having used the named drug  
at the time they were surveyed. A person who records 
lifetime prevalence may or may not be currently using 
the drug. Lifetime prevalence should not be interpreted 
as meaning that people have necessarily used a drug 
over a long period of time or that they will use the drug 
in future. However lifetime information is a core EMCDDA 
requirement, allowing analysis and international comparisons 
of outcomes e.g. continuation/discontinuation rates.
Last year prevalence refers to the proportion of the 
sample that reported using a named drug in the year prior 
to the survey. Last year prevalence is often referred to as 
recent use.
1 Since January 2005 the Health Boards in Ireland have been restructured and merged under one authority, the Health Service Executive. For the purpose of 
facilitating comparisons between the 2002/3, 2006/7 and the current survey, it was decided to continue to weight the data by the former Health Board areas 
as these correspond with the Regional Drug Task Force structures.
2 The composition of the population in Ireland changed substantially since Census 2006. Given that Census 2011 information was not available when weights 
were calculated, data were weighted using 2010 population estimates. For the purpose of constructing post-stratification weights, Regional Authority areas were 
used to define regions instead of Health Board/RDTF.
3 Since the 2006/7 Survey the Health and Social Services Boards and the Health and Social Care Trusts have been restructured. In the 2010/11 survey the data 
have been weighted by the 5 Health and Social Care Trust areas, while in the previous two surveys the data was weighted by the 4 Health and Social Services 
Boards that existed at the time.
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What is Prevalence? continued
Last month prevalence refers to the proportion of the 
sample that reported using a named drug in the 30 day 
period prior to the survey. Last month prevalence is often 
referred to as current use. A proportion of those reporting 
current use may be occasional (or first-time) users who 
happen to have used in the period leading up to the  
survey – it should therefore be noted that current use  
is not synonymous with regular use.
As with other European surveys, people over the age of 
64 are excluded from this survey as they grew up in an 
era when both the use and availability of illegal drugs were 
very limited. Therefore surveys with older people have, to 
date, shown very low rates of use even on a lifetime basis. 
However, this situation is likely to change over time as the 
younger population grows older and will be kept under 
review. Hence, lifetime prevalence rates are likely to increase 
for a considerable period of time. When examining the data 
and comparing results for illicit drugs over time, last year use 
is the best reflection of change as it refers to recent use.
Understanding the Results of 
this Bulletin
This bulletin contains prevalence rates and other relevant 
information regarding current polydrug use; that is, the use of more 
than one substance within the last month (last 30 days), in Ireland 
for 2010/11. Results are given for all respondents (all adults 
aged 15-64 years) and for gender and age (15-34 and 35-64 
years) categories based on data provided for last month use.
Due to changes in the combinations of polydrug use since the 
last survey, comparisons between 2010/11 and earlier survey 
results are not presented for prevalence of use. Comparisons 
between 2010/11 and earlier survey results are presented for 
use of one substance by users of another substance.
All prevalence rates presented in the accompanying tables 
are rounded to one decimal place and are rounded to whole 
numbers in the text. Where it provides for a better understanding 
of the situation, figures are sometimes reported in the text at 
one decimal place (e.g. small/low figures).
Invalid responses have been excluded from all analyses. Percentages 
may not always sum to 100 due to either the effect of rounding 
or where respondents may have given more than one answer.
For the purpose of this study:
n ‘Legal drugs’ refers to alcohol, tobacco, sedatives or 
tranquillisers, anti-depressants and ‘other legal drugs’. Due 
to small numbers methadone, other opiates4 and anabolic 
steroids are grouped as ‘other legal drugs’
n ‘Any illegal drugs’ refers to amphetamines, cannabis, cocaine 
powder, crack, ecstasy, heroin, LSD, magic mushrooms, 
poppers and solvents
n ‘No legal or illegal drugs’ refers to none of the above 
specified (legal or illegal) drugs in the last month
Reliability of the Estimates
Effects of survey design and statistical significance: 
The vast majority of surveys employ complex design features 
including stratification and clustering as well as weighting 
adjustments. These features greatly improve the efficiency 
and coverage of the survey but their effects must be taken 
into account in data analysis and estimation. The analyses for 
the 2010/11 NACD/A Bulletins incorporate these effects and 
are addressed in the following ways:
(i) The confidence intervals for prevalence estimates are design 
effect adjusted using the Clopper Pearson method;
(ii) For the change in prevalence over time, significance levels 
are calculated on the basis of design-effect adjusted 
Newcombe-Wilson Hybrid Confidence Intervals;
(iii) Ordinal and non-normally distributed metric outcomes are 
modelled in an ordinal regression framework with Wald 
F-Test as significance test. This is the equivalent of a  
Mann-Whitney-Wilcoxon test for complex surveys5;
(iv) Similarly, the significance of associations between prevalence 
rates and multi-categorical grouping variables is tested by 
Wald F-Tests for logistic regression models.
The tests of statistical significance are used to establish the 
degree of confidence with which we can infer that the observed 
changes in drug prevalence between 2010/11 and 2006/7 are 
not due to sampling error. For the change in prevalence over 
time, a significance level of 5% has been specified which means 
that the likelihood that sampling error accounts for the observed 
change is less than 5%. More stringent criteria are used for the 
tests of association for instance between prevalence and socio-
economic group: for these, significance levels of 1% and 0.1% 
are used. For greater transparency the actual significance level 
p rather than the threshold value is reported when discussing 
results of tests of association.
4 Opium, Temgesic®, Diconal®, Napps, MSTs®, Pethidine, DF118®, (Dihydrocodeine), Buprenorphine and Morphine, Codeine, Feminax, Kapake, Diffs, Dikes, 
Peach, Fentanyl (Durogesic®, Sublimaze®, Actiq®), Oxycodone (Oxycontin®, Oxynorm®), and Buprenorphine (Subutex®), Maxilief, Migraleve, Nurofen Plus, 
Codeine Phosp, Panadeine, Paracetamol/Caffeine/Codeine and Doxylamine, Paracodin, Paramol, Solpadeine, Solpadol, Syndol, Tylex, Uniflu Plus, Veganin Plus.
5 Natarajan S, Lipsitz S, Fitzmaurice GM, Sinha D, Ibrahim JG, Haas J, Gellad W, An extension of the Wilcoxon rank sum test for complex sample survey data, 
Journal of the Royal Statistical Society, Applied Statistics (2012), 61/4: 653-644.
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In statistical testing, a result is deemed statistically significant if 
it is unlikely to have occurred by chance, and hence provides 
enough evidence to reject the hypothesis of ‘no effect’. As used 
in statistics, significant does not mean important or meaningful, 
as it does in everyday speech. It is important to realise that 
statistical significance and substantive or practical significance 
are not the same. A small, but important, real-world difference 
may fail to reach significance in a statistical test. Conversely, a 
statistically significant finding may have no practical consequence. 
This is especially important to remember when working with 
large sample sizes because any difference can be statistically 
significant if the samples are extremely large. Whether the 
change is of practical importance is reflected in an evaluation 
of effect size, which is a substantive issue.
Robustness: Sometimes bivariate association can be 
confounded by other variables most notably gender and age. 
Where this is the case in the reporting of Ireland data, it is noted 
in the text and findings that are not robust are not included in 
the key findings section.
Limitations of the General Population Survey 
Methodology
A general population drug prevalence survey has some 
limitations. Some groups with high drug use prevalence are not 
covered by the general population survey method (for example 
the homeless, those in prison). Additionally, drug prevalence 
questions are considered to be sensitive and therefore people 
may refuse to participate or they may under-report their drug 
use. Moreover, for some groups the numbers can be too small 
for reliable prevalence estimations and for these specific groups, 
general population prevalence estimates can be supplemented 
by other methods (e.g. capture-recapture for problem drug 
use and surveys targeting special populations (e.g. prisoners, 
students, early school leavers)).
Details of all drug prevalence estimates with 95% confidence 
intervals have been calculated and are available at the NACDA 
website.
Definition of Polydrug Use
There are a number of forms of polydrug use. The most general 
definition of polydrug use (and the form reported in this bulletin) 
is concurrent substance use, which involves a person using at 
least two substances during the same time period (for example 
having used both cocaine and ecstasy in the last month).
Polydrug use is associated with a number of negative 
consequences including mental and physical ill-health, violence, 
aggression and a range of social problems. Polydrug use is more 
likely to result in accidents and death (including death from 
overdose) than when a single substance is consumed.
There is evidence that polydrug use is common among people 
seeking drug treatment. The majority of cases treated in 2010 in 
Ireland reported problem drug use of more than one substance 
(65%) (HRB 2011)6. Polydrug use is more complex to treat, 
requiring services that can treat both alcohol and other drug 
dependence while providing a broad range of interventions, and 
is associated with poorer treatment outcomes. Earlier research 
shows that the pattern of use of ‘additional’ substances was 
linked to the main problem substance, the most common 
additional problem substances were cannabis followed by 
cocaine and benzodiazepines.6
In considering the results presented here, note that the figures 
for prevalence are for that specific combination of drugs 
ONLY. Thus, the figures for alcohol only refers to that group 
of people who consumed alcohol only, i.e. that group did not 
use any other substance during that specified interval. A higher 
percentage than this will actually have consumed alcohol, but 
will also have used another substance (for example, smoke 
tobacco). The important point is that the tables presented in 
this bulletin are not aimed at presenting information on the 
prevalence of individual substances, but rather at the prevalence 
of the combination of drugs.
RESULTS – IRELAND
Polydrug Use – Last Month 
Prevalence
All adults (Table 1)
Results from the 2010/11 survey in Ireland show that among 
all adults aged 15-64 years, 20% had not used any substance 
(legal or illegal) in the last month. In other words a large 
proportion of adults aged 15-64 were not current users of 
any substance, legal or illegal.
The largest proportion of respondents (39%) had consumed 
alcohol only; the most frequently reported combination of 
polydrug use involved the two most familiar substances, alcohol 
and tobacco (16%). Four percent of respondents had used 
tobacco only.
Apart from the combination of alcohol and tobacco, the last 
month prevalence rates of all other combinations of polydrug 
use were low. The second most frequently reported combination 
of polydrug use was alcohol and other legal drugs (7%) followed 
by alcohol, tobacco and other legal drugs (2%) and alcohol, 
6 Alcohol and Drug Research Unit of the Health Research Board (2011) Trends in treated problem drug use in Ireland, 2005 to 2010.  
Available at http://www.hrb.ie/publications.
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tobacco and any illegal drugs (2%). The proportion of all adults 
reporting various other polydrug use combinations ranged from 
less than 0.1% to 0.9%. The total last month prevalence rate 
for all polydrug use combinations which included any illegal 
drug was 3%. The total last month prevalence rate for all other 
polydrug use combinations was 4%.
Again it should be noted that prevalence rates are for the specific 
combination of substances ONLY and do not indicate the level of 
consumption of any individual substance on its own.
Gender (Tables 2 & 3)
A higher percentage of females (23%) than males (16%) had 
not used any substance (legal or illegal) during the last month. 
Also, higher percentages of women than men reported using 
the following combinations: alcohol and other legal drugs (8% 
vs. 5%); tobacco only (5% vs. 4%); alcohol, tobacco and other 
legal drugs (3% vs. 2%); alcohol and anti-depressants (1% vs. 
0.6%); and alcohol, tobacco and anti-depressants (1% vs. 0.4%).
Men were more likely than women to report alcohol as the only 
substance used during the last month (42% vs. 36%). Higher 
percentages of men than women reported using alcohol and 
tobacco (20% vs. 13%); alcohol, tobacco and any illegal drugs 
(3% vs. 0.4%); alcohol and any illegal drugs (0.7% vs. 0.1%) 
and alcohol, other legal drugs and any illegal drugs (0.3% vs. 
0.0%).
These differences in 2010/11 men and women’s last month 
prevalence rates were statistically significant.
Age Table (4 & 5)
Similar percentages of young adults (15-34 years) and 
older adults (35-64 years) reported they had not used any 
drugs (legal or illegal) during the last month; 21% and 19% 
respectively. Also, similar percentages of young and older adults 
reported they had used tobacco only (4% vs. 5%) and the 
following combinations during the last month: alcohol and other 
legal drugs (6% vs. 7%) and alcohol, tobacco and other legal 
drugs (3% vs. 2%).
Last month prevalence of alcohol and tobacco was higher 
among young adults (18%) than older adults (15%). Also last 
month prevalence rates were higher among young adults than 
older adults for the combination of alcohol, tobacco and any 
illegal drugs (3% vs. 0.7%); and the combination of alcohol 
and any illegal drugs was higher among young adults (1%) than 
older adults (0.1%).
However, higher percentages of older adults than young adults 
reported they had used the following combinations: alcohol 
and anti-depressants (1% vs. 0.4%); alcohol, tobacco and 
sedatives or tranquillisers (0.5% vs. 0%) and alcohol, sedatives 
or tranquillisers and anti-depressants (0.3% vs. 0.1%) during the 
last month.
These differences in 2010/11 young and older adults’ last 
month prevalence rates were statistically significant.
Relationship between use of particular 
substances and use of other substances – 
All adults (Table 6)
Patterns of polydrug use change when the data for specific 
drugs used was analysed. Table 6 presents 2010/11 patterns 
of association between the use of one substance and the use 
of another substance. For example, of those respondents who 
used alcohol (3,621), 31% also used tobacco and 3% also used 
cannabis in the last month.
In general the commonly used legal substances (alcohol and 
tobacco) were associated with less use of other substances 
than vice versa. Of those who had smoked tobacco in the last 
month, 78% had also drunk alcohol. However, for both alcohol 
and tobacco the proportion of respondents using them in 
combination with other legal or illegal drugs was low; last month 
prevalence of cocaine use among users of alcohol was 0.7% 
and among tobacco users was 1%.
In contrast, users of cannabis, amphetamine-type stimulants 
and cocaine were more likely to have used other legal as well 
as illegal substances. Of those who had used cannabis within 
the last month, 85% had also used alcohol and 77% had 
also smoked tobacco. Of those who had used cocaine within 
the last month, all respondents (100%) reported also using 
alcohol, 77% smoked tobacco, 41% used cannabis, 14% used 
amphetamine-type stimulants and 12% used anti-depressants.
Since the previous survey in 2006/7, the last month prevalence 
of tobacco use among users of alcohol decreased (-4.7 
percentage points), while the last month prevalence of anti-
depressant use by users of alcohol increased (+1.1 percentage 
points). There were also decreases in use of alcohol among 
users of tobacco (-2.9 percentage points), use of tobacco 
among users of cannabis (-11.6 percentage points) and use 
of sedatives or tranquillisers among users of anti-depressants 
(-12.1 percentage points). Since 2006/7, there were decreases 
in the last month prevalence of amphetamine-type stimulant use 
among users of cannabis (-9.5 percentage points), among users 
of tobacco (-0.7 percentage points) and among users of alcohol 
(-0.4 percentage points).
Relationship between use of particular 
substances and use of other substances – 
Gender (Tables 7 & 8)
Table 7 and Table 8 present patterns of association between 
the use of one substance and the use of another substance for 
men and for women in 2010/11. Among users of alcohol, men 
were more likely than women to have smoked tobacco (34% vs. 
28%). Similarly among users of alcohol men were more likely 
Drug use in Ireland and Northern Ireland: 2010/11 Drug Prevalence Survey:  
Polydrug Use Results
7National Advisory Committee on Drugs and Alcohol 2014
than women to have used cannabis (5% vs. 1%). However, 
more women than men who were users of alcohol reported 
they had also used anti-depressants (5% vs. 2%) during the last 
month.
Among users of tobacco, men were more likely than women to 
have also used alcohol (83% vs. 73%). Similarly, among users 
of tobacco, men were more likely than women to have used 
cannabis (11% vs. 3%) while larger proportions of women 
than men reported also using anti-depressants (9% vs. 5%) 
within the last month. Of those who had used sedatives or 
tranquillisers, last month prevalence of cannabis use was higher 
among men than women (15% vs. 5%). There were no other 
statistically significant differences in the use of one substance by 
users of another substance among men and women.
Since 2006/7, there was a decrease in the use of tobacco 
among men who were users of alcohol (-3.4 percentage points). 
Similarly, there was a decrease in the use of tobacco among 
men who were users of cannabis (-14.8 percentage points) and 
a decrease in the use of alcohol (-4.5 percentage points) among 
men who were users of tobacco. Since 2006/7, there were also 
decreases in the last month prevalence of amphetamine-type 
stimulant use among men who were users of cannabis (-8.9 
percentage points) and among men who were users of alcohol 
(-0.5 percentage points).
Since 2006/7, the only statistically significant changes in use of 
one substance by users of another substance among women 
were a decrease in the use of tobacco among users of alcohol 
(-6.2 percentage points) and an increase in the use of anti-
depressants among users of alcohol (+1.8 percentage points).
Relationship between use of particular 
substances and use of other substances – 
Age (Tables 9 & 10)
Differences between young adults (15-34 years) and older 
adults (35-64 years) in the use of more than one substance 
were observed, mainly for alcohol and tobacco. Among users 
of alcohol:
n Young adults were more likely than older adults to have 
reported also using tobacco (36% vs. 27%)
n Young adults were more likely than older adults to have 
reported also using cannabis (6% vs. 2%)
n Young adults were more likely than older adults to have 
reported also using cocaine (1% vs. 0.2%)
However, a higher percentage of older adult than young adult 
users of alcohol reported they had also used anti-depressants 
(5% vs. 2%). Likewise, the use of sedatives or tranquillisers 
was also higher among older adult than younger adult users 
of alcohol (4% vs. 1%).
Similar results were observed among users of tobacco:
n Young adults were more likely than older adults to have 
reported also using alcohol (82% vs. 75%)
n Young adults were more likely than older adults to have 
reported also using cannabis (11% vs. 4%)
n Young adults were more likely than older adults to have 
reported also using cocaine (2% vs. 0.5%).
However, a higher percentage of older adult than young 
adult users of tobacco reported that they had also used anti-
depressants (8% vs. 5%). The use of sedatives or tranquillisers 
was also higher among older adult than younger adult users of 
tobacco (7% vs. 2%).
There were some further differences between young and older 
adults in the use of more than one substance, such as cannabis, 
cocaine, sedatives or tranquillisers and anti-depressants. Among 
users of cannabis, older adults were more likely than young 
adults to also use sedatives or tranquillisers (24% vs. 3%), 
with similar results for use of anti-depressants among users 
of cannabis (20% vs. 5%). Similarly among cocaine users:
n Older adults were more likely than young adults to have 
reported also using amphetamine-type stimulants  
(79% vs. 3%)
n Older adults were more likely than young adults to have 
reported also anti-depressants (52% vs. 5%)
Among users of anti-depressants, older adults were more likely 
than young adults to have used sedatives or tranquillisers (31% 
vs.13%) while, more young than older adult users of anti-
depressants had used tobacco within the last month (64% vs. 
37%). However, of users of sedatives or tranquillisers, young 
adults were more likely than older adults to have also used 
cocaine (11% vs. 0.3%).
Since 2006/7, last month prevalence of tobacco use decreased 
among young adult (-4.9 percentage points) and older adult 
(-4.1 percentage points) users of alcohol. Similarly last month 
prevalence of tobacco use among young adults users of 
cannabis also decreased (-14.3 percentage points).
Since 2006/7, last month prevalence of amphetamine-type 
stimulant use decreased among young adult users of cannabis 
(-13.4 percentage points), among young adult users of tobacco 
(-1.5 percentage points) and among young adult users of 
alcohol (-0.9 percentage points). Among older adult users of 
alcohol, there was an increase in the use of anti-depressants 
(+1.6 percentage points) since 2006/7. There were decreases 
in the use of tobacco (-13.2 percentage points) and the use of 
sedatives or tranquillisers (-15.1 percentage points) among older 
adult users of anti-depressants.
In conclusion, the results of the prevalence of polydrug use 
among the general population are presented in this bulletin with 
the key findings highlighted above.
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Table 1: Top 30 of last month prevalence of no drug, monodrug and polydrug use – All adults (15-64)
Substance Frequency  
n=5120
Percent
Alcohol 2001 39.1
No drug 1002 19.6
Alcohol and Tobacco 831 16.2
Alcohol and Other legal drugs 342 6.7
Tobacco 214 4.2
Alcohol, Tobacco and Other legal drugs 125 2.4
Other legal drugs 121 2.4
Alcohol, Tobacco and Any illegal drugs 81 1.6
Tobacco and Other legal drugs 46 0.9
Alcohol and Anti-depressants 45 0.9
Alcohol, Tobacco and Anti-depressants 33 0.6
Anti-depressants 30 0.6
Alcohol and Any illegal drugs 21 0.4
Alcohol and Sedatives or Tranquillisers 21 0.4
Alcohol, Tobacco and Sedatives or Tranquillisers 17 0.3
Alcohol, Tobacco, Other legal drugs and Any illegal drugs 14 0.3
Tobacco and Anti-depressants 14 0.3
Alcohol, Sedatives or Tranquillisers and Other legal drugs 12 0.2
Alcohol, Anti-depressants and Other legal drugs 12 0.2
Sedatives or Tranquillisers 11 0.2
Tobacco and Sedatives or Tranquillisers 10 0.2
Alcohol, Sedatives or Tranquillisers and Anti-depressants 10 0.2
Alcohol, Tobacco, Sedatives or Tranquillisers and Anti-depressants 9 0.2
Alcohol, Other legal drugs and Any illegal drugs 8 0.2
Tobacco and Any illegal drugs 7 0.1
Alcohol, Sedatives or Tranquillisers, Anti-depressants and Other legal drugs 7 0.1
Any illegal drugs 6 0.1
Sedatives or Tranquillisers and Anti-depressants 6 0.1
Alcohol, Tobacco, Anti-depressants and Other legal drugs 6 0.1
Tobacco, Anti-depressants and Other legal drugs 5 0.1
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 2: Top 30 of last month prevalence of no drug, monodrug and polydrug use – Males
Substance Frequency  
n=2551
Percent
Alcohola 1077 42.2
Alcohol and Tobaccoa 497 19.5
No druga 410 16.1
Alcohol and Other legal drugsa 137 5.4
Tobaccoa 89 3.5
Alcohol, Tobacco and Any illegal drugsa 72 2.8
Alcohol, Tobacco and Other legal drugsa 51 2.0
Other legal drugsa 30 1.2
Tobacco and Other legal drugs 19 0.7
Alcohol and Any illegal drugsa 18 0.7
Alcohol and Anti-depressantsa 14 0.6
Anti-depressants 14 0.5
Alcohol, Tobacco and Anti-depressantsa 10 0.4
Alcohol, Tobacco, Other legal drugs and Any illegal drugs 9 0.4
Alcohol, Tobacco and Sedatives or Tranquillisers 9 0.4
Alcohol and Sedatives or Tranquillisers 9 0.3
Alcohol, Other legal drugs and Any illegal drugsa 8 0.3
Alcohol, Sedatives or Tranquillisers and Other legal drugs 7 0.3
Any illegal drugs 6 0.2
Alcohol, Anti-depressants and Other legal drugs 6 0.2
Tobacco and Any illegal drugs 5 0.2
Tobacco, Anti-depressants and Other legal drugs 5 0.2
Sedatives or Tranquillisers 5 0.2
Tobacco and Anti-depressants 4 0.2
Sedatives or Tranquillisers and Anti-depressants 3 0.1
Alcohol, Sedatives or Tranquillisers and Anti-depressants 3 0.1
Alcohol, Tobacco, Anti-depressants and Other legal drugs 3 0.1
Alcohol, Tobacco, Sedatives or Tranquillisers and Anti-depressants 3 0.1
Tobacco and Sedatives or Tranquillisers 2 0.1
Alcohol, Sedatives or Tranquillisers, Anti-depressants and Other legal drugs 2 0.1
a Denotes a statistically significant difference between men and women in 2010/2011
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 3: Top 30 of the last month prevalence of no drug, monodrug and polydrug use – Females
Substance Frequency  
n=2569
Percent
Alcohola 924 36.0
No druga 592 23.1
Alcohol and Tobaccoa 334 13.0
Alcohol and Other legal drugsa 205 8.0
Tobaccoa 124 4.8
Other legal drugsa 91 3.5
Alcohol, Tobacco and Other legal drugsa 74 2.9
Alcohol and Anti-depressantsa 31 1.2
Tobacco and Other legal drugs 27 1.0
Alcohol, Tobacco and Anti-depressantsa 24 0.9
Anti-depressants 16 0.6
Alcohol and Sedatives or Tranquillisers 12 0.5
Tobacco and Anti-depressants 10 0.4
Alcohol, Tobacco and Any illegal drugsa 9 0.4
Tobacco and Sedatives or Tranquillisers 8 0.3
Alcohol, Tobacco and Sedatives or Tranquillisers 7 0.3
Alcohol, Sedatives or Tranquillisers and Anti-depressants 7 0.3
Sedatives or Tranquillisers 7 0.3
Alcohol, Anti-depressants and Other legal drugs 6 0.2
Alcohol, Tobacco, Sedatives or Tranquillisers and Anti-depressants 6 0.2
Alcohol, Sedatives or Tranquillisers and Other legal drugs 5 0.2
Alcohol, Tobacco, Other legal drugs and Any illegal drugs 5 0.2
Alcohol, Sedatives or Tranquillisers, Anti-depressants and Other legal drugs 5 0.2
Alcohol and Any illegal drugsa 3 0.1
Alcohol, Tobacco, Anti-depressants and Other legal drugs 2 0.1
Sedatives or Tranquillisers and Anti-depressants 2 0.1
Tobacco and Any illegal drugs 1 0.06
Tobacco, Anti-depressants and Other legal drugs 0 0.0
Alcohol, Other legal drugs and Any illegal drugsa 0 0.0
Any illegal drugs 0 0.0
a Denotes a statistically significant difference between men and women in 2010/2011
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 4: Top 30 of the last month prevalence of no drug, monodrug and polydrug use – Young adults (15-34)
Substance Frequency  
n=2251
Percent
Alcohol 830 36.9
No drug 468 20.8
Alcohol and Tobaccoa 403 17.9
Alcohol and Other legal drugs 140 6.2
Tobacco 78 3.5
Alcohol, Tobacco and Other legal drugs 76 3.4
Alcohol, Tobacco and Any illegal drugsa 62 2.8
Other legal drugs 51 2.3
Tobacco and Other legal drugs 26 1.2
Alcohol and Any illegal drugsa 18 0.8
Alcohol, Tobacco and Anti-depressants 16 0.7
Alcohol, Tobacco, Other legal drugs and Any illegal drugs 14 0.6
Alcohol and Anti-depressantsa 9 0.4
Tobacco and Anti-depressants 7 0.3
Anti-depressantsa 5 0.2
Alcohol and Sedatives or Tranquillisers 5 0.2
Alcohol, Other legal drugs and Any illegal drugs 5 0.2
Any illegal drugs 5 0.2
Tobacco and Any illegal drugs 4 0.2
Alcohol, Sedatives or Tranquillisers and Other legal drugs 2 0.1
Alcohol, Anti-depressants and Other legal drugs 2 0.1
Tobacco and Sedatives or Tranquillisers 2 0.1
Sedatives or Tranquillisers 2 0.1
Alcohol, Tobacco, Anti-depressants and Other legal drugs 1 0.06
Alcohol, Sedatives or Tranquillisers and Anti-depressantsa 1 0.05
Alcohol, Tobacco and Sedatives or Tranquillisersa 1 0.03
Alcohol, Tobacco, Sedatives or Tranquillisers and Anti-depressants 0 0
Alcohol, Sedatives or Tranquillisers, Anti-depressants and Other legal drugs 0 0
Sedatives or Tranquillisers and Anti-depressants 0 0
Tobacco, Anti-depressants and Other legal drugs 0 0
a Denotes a statistically significant difference between age groups in 2010/2011
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 5: Top 30 of last month prevalence of no drug, monodrug and polydrug use – Older adults (35-64)
Substance Frequency  
n=2869
Percent
Alcohol 1172 40.8
No drug 534 18.6
Alcohol and Tobaccoa 428 14.9
Alcohol and Other legal drugs 201 7.0
Tobacco 135 4.7
Other legal drugs 70 2.4
Alcohol, Tobacco and Other legal drugs 49 1.7
Alcohol and Anti-depressantsa 36 1.3
Anti-depressantsa 25 0.9
Tobacco and Other legal drugs 19 0.7
Alcohol, Tobacco and Any illegal drugsa 19 0.7
Alcohol, Tobacco and Anti-depressants 17 0.6
Alcohol and Sedatives or Tranquillisers 16 0.6
Alcohol, Tobacco and Sedatives or Tranquillisersa 16 0.5
Sedatives or Tranquillisers 10 0.3
Alcohol, Anti-depressants and Other legal drugs 10 0.3
Alcohol, Sedatives or Tranquillisers and Other legal drugs 10 0.3
Alcohol, Sedatives or Tranquillisers and Anti-depressantsa 9 0.3
Alcohol, Tobacco, Sedatives or Tranquillisers and Anti-depressants 9 0.3
Tobacco and Sedatives or Tranquillisers 8 0.3
Alcohol, Sedatives or Tranquillisers, Anti-depressants and Other legal drugs 7 0.2
Tobacco and Anti-depressants 7 0.2
Sedatives or Tranquillisers and Anti-depressants 6 0.2
Tobacco, Anti-depressants and Other legal drugs 5 0.2
Alcohol, Tobacco, Anti-depressants and Other legal drugs 4 0.2
Alcohol and Any illegal drugsa 4 0.1
Tobacco and Any illegal drugs 3 0.1
Alcohol, Other legal drugs and Any illegal drugs 3 0.1
Any illegal drugs 1 0.05
Alcohol, Tobacco, Other legal drugs and Any illegal drugs 0 0.0
a Denotes a statistically significant difference between age groups in 2010/2011
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
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Table 6: Total number of users of one substance by users of another substance and related percentages –  
All adults (15-64)
Last Month 
Prevalence
Users of 
Alcohol
Users of 
Tobacco
Users of 
Cannabis
Users  
of ATS1
Users of 
Cocaine
Users  
of ST2
Users  
of AD3
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total weighted N 4967 5126 3653 3621 1619 1451 128 143 19 5 25 26 147 142 154 209
Alcohol 73.4 70.6 81.2 78.3† 90.6 84.5 100.0 100.0 100.0 100.0 65.3 65.2 62.1 63.5
Tobacco 32.6 28.3 36.1 31.4† 88.3 76.7† 84.2 88.3 80.0 77.2 45.6 46.1 50.0 43.5
Cannabis 2.6 2.8 3.2 3.3 7.0 7.6 78.9 62.4 60.0 40.9 4.7 9.0 5.8 6.1
ATS1 0.4 0.1 0.5 0.1† 1.0 0.3† 11.7 2.2† 25.0 14.1 0.7 0.4 0.6 1.2
Cocaine 0.5 0.5 0.7 0.7 1.2 1.4 11.7 7.4 33.3 74.1 0.7 2.1 0.0 1.5
ST2 3.0 2.8 2.6 2.6 4.1 4.5 5.5 9.0 5.3 11.7 4.0 11.4 38.3 26.2†
AD3 3.1 4.1 2.6 3.7† 4.8 6.3 7.0 8.9 5.3 52.9† 0.0 12.4 40.1 38.5
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11
a Denotes a statistically significant difference between gender in 2010/2011
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
Table 7: Total number of users of one substance by users of another substance and related percentages – Males
Last Month 
Prevalence
Users of 
Alcohol
Users of 
Tobacco
Users of 
Cannabis
Users  
of ATS1
Users of 
Cocaine
Users  
of ST2
Users  
of AD3
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total weighted N 2513 2554 1966 1946 844 800 99 119 13 4 19 19 60 58 58 80
Alcohol 78.2 76.3 87.6 83.1a† 92.0 84.4 100.0 100.0 100.0 100.0 63.9 70.6 63.8 55.7
Tobacco 33.6 31.3 37.6 34.2a† 89.9 75.1† 92.3 100.0 84.2 75.6 47.5 49.2 48.3 44.8
Cannabis 4.0 4.7 4.7 5.2a 10.5 11.2a 84.6 67.0 63.2 49.7 6.6 15.3a 8.6 10.9
ATS1 0.5 0.2 0.7 0.2† 1.4 0.5 11.1 2.2† 26.3 13.5 0.0 0 0.0 2.5
Cocaine 0.7 0.8 1.0 1.0 1.9 1.8 12.0 8.0 38.5 67.0 0.0 1.4 0.0 2.5
ST2 2.4 2.3 2.0 2.1 3.4 3.5 4.0 7.4 0.0 0.0 0.0 4.1 38.6 23.8
AD3 2.3 3.2 1.9 2.3a 3.3 4.5a 5.1 7.3 0.0 52.5† 0.0 10.5 36.7 33.2
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11
a Denotes a statistically significant difference between gender in 2010/2011
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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Table 8: Total number of users of one substance by users of another substance and related percentages – Females
Last Month 
Prevalence
Users of 
Alcohol
Users of 
Tobacco
Users of 
Cannabis
Users  
of ATS1
Users of 
Cocaine
Users  
of ST2
Users  
of AD3
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total weighted N 2454 2572 1678 1673 776 651 28 24 6 1 6 7 87 85 96 129
Alcohol 68.4 65.1 74.4 72.5a 85.7 85.1 100.0 100.00 100.0 100.0 66.3 61.5 61.5 68.3
Tobacco 31.6 25.3 34.4 28.2a† 85.7 84.7 80.0 45.8 80.0 81.8 44.8 44.0 51.0 42.8
Cannabis 1.1 0.9 1.4 1.2a 3.1 3.1a 60.0 45.8 50.0 15.8 3.4 4.8a 3.2 3.1
ATS1 0.2 0.04 0.4 0.1 0.5 0.1 10.7 2.1 33.3 15.8 1.1 0.7 1.0 0.4
Cocaine 0.2 0.3 0.4 0.4 0.5 0.8 10.7 4.5 33.3 100.0 1.1 2.5 0.0 0.9
ST2 3.5 3.3 3.4 3.1 5.0 5.7 10.7 17.1 16.7 54.2 16.7 32.1 38.5 27.7
AD3 3.9 5.0 3.5 5.3a† 6.3 8.5a 10.7 17.0 16.7 54.2 0.0 17.5 42.5 42.1
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11
a Denotes a statistically significant difference between gender in 2010/2011
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
Table 9: Total number of users of one substance by users of another substance and related percentages –  
Young adults (15-34)
Last Month 
Prevalence
Users of 
Alcohol
Users of 
Tobacco
Users of 
Cannabis
Users  
of ATS1
Users of 
Cocaine
Users  
of ST2
Users  
of AD3
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total weighted N 2315 2254 1709 1597 833 706 97 102 17 2 23 22 30 24 50 51
Alcohol 73.8 70.9 84.8 82.4a 93.8 86.4 100.0 100.0 100.0 100.0 70.0 69.7 68.0 68.5
Tobacco 36.0 31.3 41.3 36.4a† 89.7 75.4† 82.4 68.9 78.3 73.2 48.3 48.0 50.0 64.3a
Cannabis 4.2 4.5 5.3 5.5a 10.4 11.0a 76.5 0.0† 58.3 34.2 3.3 13.3 7.8 9.5
ATS1 0.7 0.1 1.0 0.1† 1.7 0.2† 13.4 0.0† 21.7 2.6a 3.3 2.4 2.0 1.1
Cocaine 1.0 1.0 1.3 1.4a 2.2 2.3a 14.4 7.4 31.3 31.1 3.3 10.8a 0.0 2.3
ST2 1.3 1.0 1.2 1.0a 1.7 1.6a 1.0 3.1a 5.9 31.1 4.2 11.5 24.0 13.1a
AD3 2.2 2.3 2.0 2.2a 3.0 4.7a 4.1 4.7a 5.9 31.1 0.0 5.3a 40.0 28.4
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11
a Denotes a statistically significant difference between age groups in 2010/2011
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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Table 10: Total number of users of one substance by users of another substance and related percentages –  
Older adults (35-64)
Last Month 
Prevalence
Users of 
Alcohol
Users of 
Tobacco
Users of 
Cannabis
Users  
of ATS1
Users of 
Cocaine
Users  
of ST2
Users  
of AD3
06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11 06/7 10/11
Total weighted N 2652 2872 1935 2023 787 745 31 41 2 3 1 4 118 119 103 158
Alcohol 73.0 70.4 77.5 74.5a 80.6 79.7 100.0 100.0 100.0 100.0 64.1 64.3 59.2 61.8
Tobacco 29.7 25.9 31.5 27.4a† 83.9 79.8 100.0 100.0 100.0 100.0 44.9 45.7 50.0 36.8a†
Cannabis 1.2 1.4 1.3 1.6a 3.3 4.3a 100.0 100.0 100.0 79.2 5.1 8.2 4.9 5.0
ATS1 0.1 0.1 0.1 0.2 0.3 0.4 6.5 7.6 100.0 79.2a 0.0 0.0 0.0 1.3
Cocaine 0.0 0.1 0.1 0.2a 0.1 0.5a 3.3 7.6 50.0 100.0 0.0 0.3a 0.0 1.3
ST2 4.4 4.1 3.9 3.8a 6.7 7.3a 19.4 24.0a 0.0 0.0 0.0 10.4 45.6 30.5a†
AD3 3.9 5.5 3.2 4.8a† 6.6 7.8a 16.7 19.5a 0.0 66.0 0.0 52.2a 39.8 40.5
All figures are based on weighted data, are rounded to the nearest decimal place and based on valid responses.
† Denotes a statistically significant change (p<0.05) between 2006/7 and 2010/11
a Denotes a statistically significant difference between age groups in 2010/2011
1 ATS – Amphetamine-type stimulants (Ecstasy and Amphetamines)
2 ST – Sedatives or Tranquillisers
3 AD – Anti-depressants
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